Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2016 · 10-Q
Revenue$42.50M$42.50M±0.0% vs Q1 2015 Net Income-$19.82M-$19.82MN/M vs Q1 2015 EPS Diluted-$0.12-$0.12N/M vs Q1 2015 Gross Profit$5,178,000±0.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flow-$13,023,000N/M Free Cash Flowderived-$14,122,000N/M Margins · derivedGross margin12.2%±0.0 pt vs Q1 2015
Operating margin-38.0%−5.3 pt vs Q1 2015
Net margin-46.6%±0.0 pt vs Q1 2015
ended Mar 31, 2016 · filed May 9, 2016 · 39 d after period end